<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00076050</url>
  </required_header>
  <id_info>
    <org_study_id>R01AR048932</org_study_id>
    <secondary_id>R01AR048932</secondary_id>
    <secondary_id>NIAMS-114</secondary_id>
    <secondary_id>SPARE</secondary_id>
    <nct_id>NCT00076050</nct_id>
  </id_info>
  <brief_title>Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms</brief_title>
  <acronym>SPARE</acronym>
  <official_title>Bone Sparing Effects of Soy Phytoestrogens in Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if soy-derived phytoestrogens (naturally occurring
      compounds similar to estrogen) can prevent bone loss and other menopausal symptoms in women
      who have recently gone through menopause.

      Study hypothesis: Tablets of high-dose, purified soy phytoestrogens spare the normally
      occurring spinal bone loss and improve biological and other emotional changes of menopause.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The risks of bone loss and osteoporosis increase significantly after menopause. Although
      hormone therapy (HT) can spare menopausal women from bone loss and other menopausal symptoms,
      Women's Health Initiative (WHI) findings indicate significant potential health risks
      associated with HT. This has prompted women to switch from HT to naturally occurring
      compounds similar to estrogen, such as those derived from soy, in the hope that estrogens
      from plant sources can provide benefits while sparing adverse effects caused by prescribed
      estrogens. However, the long-term efficacy and safety of plant estrogens are unknown. This
      study will evaluate the effectiveness of treatment using purified soy isoflavones, a dietary
      source of phytoestrogens, in preventing bone loss, menopausal symptoms, and other changes
      associated with estrogen deficiency in young menopausal women. The &quot;Soy Phytoestrogens As
      Replacement Estrogen (SPARE)&quot; study will provide a foundation of knowledge from which
      menopausal women and their doctors can begin to make more informed decisions regarding HT and
      other treatment options.

      Enrollment into the study will occur over 3 years, with each participant taking part in the
      study for a total of 2 years. Participants will be randomly assigned to one of two groups;
      the first group will receive a 200 mg dose of soy isoflavones daily and the second group will
      receive placebo daily. There will be 10 study visits: screening, study entry, randomization
      at Month 1, six follow-up visits at Months 2, 4, 8, 12, 16, 20, and a final visit at the end
      of active participation at Month 24. At each study visit, participants will have blood drawn,
      provide urine samples, answer questionnaires, and have mammograms and bone density tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Bone Mineral Density</measure>
    <time_frame>baseline and 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Women's Health Questionnaire Score</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>This self-administered questionnaire contains 23 items, distributed among 6 factors: anxiety and depressed mood (7 items), well-being (4 items), somatic symptoms (5 items), memory and concentration (3 items), vasomotor symptoms (2 items) and sleep problems (2 items). The instrument has a structured format and the response choices consist of 4-point Likert scales ('yes definitely' to 'no, not at all'). Item scores are collapsed into a dichotomous scale, where higher scores indicate a greater level of symptomatology or difficulty; i.e., if the response is 1 or 2 (positive response), the score = 1; if the response is 3 or 4 (negative response), the score is 0. Results can be reported as a total score, where the range is 0-23, but also for each dimension. Thus, the ranges of the subscales are: for anxiety and mood 0-7, for well-being 0-4, somatic symptoms 0-5, memory and concentration 0-3, vasomotor symptoms 0-2 and sleep problems 0-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vaginal Maturation Value</measure>
    <time_frame>baseline and 2 years</time_frame>
    <description>The Vaginal Maturation Value (VMV) describes the proportion of the three vaginal epithelial cell types (parabasal, intermediate and superficial) obtained from a swab of the vaginal walls. The changes in the proportion of each type of cells reflects the degree of exposure to estrogen of the vaginal epithelium. The VMV lists the percentage of each type of cell appearing on the smear, with the total of all three values equaling 100%. The index is read from left to right; i.e. VMI of 5/40/55 represents 5% parabasal cells, 40% intermediate cells and 55% superficial cells. Exposure to estrogens results in some parabasal cells, a greater proportion of intermediate cells and few superficial cells.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Menopause</condition>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 200-mg dose of soy isoflavones daily over 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo daily over 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy isoflavones</intervention_name>
    <description>Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo soy isoflavones</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Absence of menstrual period for 12 months but not more than 5 years, or absence of
             menstrual period for 6 to 12 months and follicle stimulating factor (FSH) greater than
             40 IU/L

        Exclusion Criteria

          -  Treatment with estrogens, progesterone, raloxifene, or tamoxifen

          -  Treatment with bisphosphonates, calcitonin, fluoride, or systemic corticosteroids

          -  Use of soy/herbal supplements, including DHEA, within 3 months prior to study entry

          -  Use of antibiotics in the month prior to study entry

          -  Use of prescription medication to treat hot flashes

          -  Chemical menopause, including post-chemotherapy

          -  Hyperthyroidism

          -  Hypothyroidism

          -  Uncontrolled diabetes

          -  Malabsorption syndromes or other chronic diseases

          -  Body mass index (BMI) less than 20 or greater than 32

          -  Bone mineral density (BMD) T-score below -2.0 in lumbar spine or femoral neck
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvina Levis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2004</study_first_submitted>
  <study_first_submitted_qc>January 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2004</study_first_posted>
  <results_first_submitted>June 26, 2013</results_first_submitted>
  <results_first_submitted_qc>October 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2016</results_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Silvina Levis, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phytoestrogens</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Soy Isoflavone Group</title>
          <description>A total of 122 participants were randomized to receive a 200-mg dose of soy isoflavones in tablet form daily by mouth, over 2 years. The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>A total of 126 participants were randomized to receive placebo tablets by mouth daily over 2 years.The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Soy Isoflavone Group</title>
          <description>A total of 122 participants were randomized to receive a 200-mg dose of soy isoflavones in tablet form daily by mouth, over 2 years. The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>A total of 126 participants were randomized to receive placebo tablets by mouth daily over 2 years.The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="248"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="3.3"/>
                    <measurement group_id="B2" value="52" spread="3.3"/>
                    <measurement group_id="B3" value="52.5" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bone Mineral Density</title>
        <time_frame>baseline and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Soy Isoflavone Group</title>
            <description>A total of 122 participants were randomized to receive a 200-mg dose of soy isoflavones in tablet form daily by mouth, over 2 years. The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>A total of 126 participants were randomized to receive placebo tablets by mouth daily over 2 years.The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bone Mineral Density</title>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.146" spread="0.125"/>
                    <measurement group_id="O2" value="1.132" spread="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Women's Health Questionnaire Score</title>
        <description>This self-administered questionnaire contains 23 items, distributed among 6 factors: anxiety and depressed mood (7 items), well-being (4 items), somatic symptoms (5 items), memory and concentration (3 items), vasomotor symptoms (2 items) and sleep problems (2 items). The instrument has a structured format and the response choices consist of 4-point Likert scales (‘yes definitely’ to ‘no, not at all’). Item scores are collapsed into a dichotomous scale, where higher scores indicate a greater level of symptomatology or difficulty; i.e., if the response is 1 or 2 (positive response), the score = 1; if the response is 3 or 4 (negative response), the score is 0. Results can be reported as a total score, where the range is 0-23, but also for each dimension. Thus, the ranges of the subscales are: for anxiety and mood 0-7, for well-being 0-4, somatic symptoms 0-5, memory and concentration 0-3, vasomotor symptoms 0-2 and sleep problems 0-2.</description>
        <time_frame>baseline and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Soy Isoflavone Group</title>
            <description>A total of 122 participants were randomized to receive a 200-mg dose of soy isoflavones in tablet form daily by mouth, over 2 years. The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>A total of 126 participants were randomized to receive placebo tablets by mouth daily over 2 years.The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Women's Health Questionnaire Score</title>
          <description>This self-administered questionnaire contains 23 items, distributed among 6 factors: anxiety and depressed mood (7 items), well-being (4 items), somatic symptoms (5 items), memory and concentration (3 items), vasomotor symptoms (2 items) and sleep problems (2 items). The instrument has a structured format and the response choices consist of 4-point Likert scales (‘yes definitely’ to ‘no, not at all’). Item scores are collapsed into a dichotomous scale, where higher scores indicate a greater level of symptomatology or difficulty; i.e., if the response is 1 or 2 (positive response), the score = 1; if the response is 3 or 4 (negative response), the score is 0. Results can be reported as a total score, where the range is 0-23, but also for each dimension. Thus, the ranges of the subscales are: for anxiety and mood 0-7, for well-being 0-4, somatic symptoms 0-5, memory and concentration 0-3, vasomotor symptoms 0-2 and sleep problems 0-2.</description>
          <units>change in score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.54"/>
                    <measurement group_id="O2" value="-0.34" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vaginal Maturation Value</title>
        <description>The Vaginal Maturation Value (VMV) describes the proportion of the three vaginal epithelial cell types (parabasal, intermediate and superficial) obtained from a swab of the vaginal walls. The changes in the proportion of each type of cells reflects the degree of exposure to estrogen of the vaginal epithelium. The VMV lists the percentage of each type of cell appearing on the smear, with the total of all three values equaling 100%. The index is read from left to right; i.e. VMI of 5/40/55 represents 5% parabasal cells, 40% intermediate cells and 55% superficial cells. Exposure to estrogens results in some parabasal cells, a greater proportion of intermediate cells and few superficial cells.</description>
        <time_frame>baseline and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Soy Isoflavone Group</title>
            <description>A total of 122 participants were randomized to receive a 200-mg dose of soy isoflavones in tablet form daily by mouth, over 2 years. The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>A total of 126 participants were randomized to receive placebo tablets by mouth daily over 2 years.The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vaginal Maturation Value</title>
          <description>The Vaginal Maturation Value (VMV) describes the proportion of the three vaginal epithelial cell types (parabasal, intermediate and superficial) obtained from a swab of the vaginal walls. The changes in the proportion of each type of cells reflects the degree of exposure to estrogen of the vaginal epithelium. The VMV lists the percentage of each type of cell appearing on the smear, with the total of all three values equaling 100%. The index is read from left to right; i.e. VMI of 5/40/55 represents 5% parabasal cells, 40% intermediate cells and 55% superficial cells. Exposure to estrogens results in some parabasal cells, a greater proportion of intermediate cells and few superficial cells.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="2.53"/>
                    <measurement group_id="O2" value="-1.78" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Soy Isoflavones</title>
          <description>A total of 122 participants were randomized to receive a 200-mg dose of soy isoflavones in tablet form daily by mouth, over 2 years. The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A total of 126 participants were randomized to receive placebo tablets by mouth daily over 2 years.The medication was delivered in four tablets that had to be taken fasting in the morning.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal bloating</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint tenderness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>tenderness lower extremities</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary track infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>vaginal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>abnormal mammogram</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory track infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hair loss</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>edema of lower exteremity</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Silvina Levis MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>305-575-3388</phone>
      <email>slevis@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

